Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: 7th Floor, Southside
105 Victoria Street
London
SW1E 6QT
UK
Tel: +44 (0)20 7630 2180
Web: http://www.bioindustry.org/home/
The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago.
Influencing Progress
Bioscience is a national priority for the UK. The BIA works to encourage and promote a financially sound and thriving bioscience sector within the UK economy.
Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, to help enable our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Lobbying is a core BIA strength. We provide a strong, unified, relentless voice for bioscience to stakeholders — including government, politicians, the media and patient advocate groups — to address the critical issues our members face and to push for progress. We educate policy makers about the needs of our members and advocate for legislation and policies essential to their growth and success.
Enabling Connections
Collaboration is key to moving bioscience forward. To support and enhance collaboration, the BIA brings together organisations from across the life sciences industry. This includes service providers, valued not only for the vital functions they serve in the sector, but also for their business acumen, expert guidance and industry connections.
The BIA hosts events throughout the year where members and others from the sector can learn, discuss, debate and network.
BIA Advisory Committee meetings connect peer groups to engage in debate and develop solutions to shared issues and challenges.
The BIA also keeps members connected and updated via regular communications. In addition, the BIA provides a host of other business development and business support services to enhance the value of membership. We facilitate introductions to other BIA members, provide meeting spaces at our central London office, offer member-only discounts to BIA and selected third-party events and also with suppliers.
In fulfilling its mission, the BIA aims to:
1 Offer a wide range of member services and benefits to the satisfaction of the membership
2 Represent the needs of the industry and its members on important issues
3 Promote best practice within the industry
4 Facilitate industry growth and maturity, positioning the UK as a leading world player in bioscience
5 Campaign for the best possible environment for innovative bioscience research
6 Communicate the benefits of innovative bioscience technologies
7 Maintain its role as the Association of choice for membership representation and communication on innovative bioscience issues
The BIA operates an active public affairs programme, a well-developed conference and and seminar programme, trade missions, regular publications for internal and external audiences, plus a series of committees whose interests range from regulatory affairs and intellectual property to personnel and finance and taxation. Networking and technology-transfer opportunities for members and others with an interest in the sector ensure that every avenue is explored in the support of UK bioscience.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen…
Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on trading regulations during this time of Brexit uncertainty. “If a transition…
The UK Prime Minister has been convinced by medical professionals to fortify all flour with folic acid to reduce the number of birth defects in newborns. A large cohort of…
This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the…
The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market. Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch…
For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions…
See our Cookie Privacy Policy Here